Musashi2 sustains the mixed-lineage leukemia'driven stem cell regulatory program

Journal of Clinical Investigation

Volumn 125, Issue 3, 2015, Pages 1286-1298

  Park, Sun Mi ^a   Gönen, Mithat ^a   Vu, Ly ^a   Minuesa, Gerard ^a   Tivnan, Patrick ^a   Barlowe, Trevor S ^a   Taggart, James ^a   Lu, Yuheng ^a   Deering, Raquel P ^b   Hacohen, Nir ^b   Figueroa, Maria E ^c   Paietta, Elisabeth ^a   Fernandez, Hugo F ^d   Tallman, Martin S ^a   Melnick, Ari ^e   Levine, Ross ^a   Leslie, Christina ^a   Lengner, Christopher J ^f   Kharas, Michael G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IKZF2 PROTEIN; MESSENGER RNA; MIXED LINEAGE LEUKEMIA PROTEIN; MYC PROTEIN; RNA BINDING PROTEIN; RNA BINDING PROTEIN MUSASHI2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG; MSI2 PROTEIN, HUMAN; PROTEIN BINDING; TRANSCRIPTOME;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; COLONY FORMATION; CONTROLLED STUDY; CORRELATIONAL STUDY; GENE DELETION; GENE EXPRESSION PROFILING; GENETIC CORRELATION; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA STEM CELL; LEUKEMOGENESIS; LOSS OF FUNCTION MUTATION; MOUSE; MURINE LEUKEMIA; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; RNA TRANSLATION; ANIMAL; C57BL MOUSE; CELL SURVIVAL; GENE EXPRESSION REGULATION; METABOLISM; MYELOID LEUKEMIA; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS; PROTEIN BINDING; RNA-BINDING PROTEINS; TRANSCRIPTOME;

EID: 84924028133     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI78440     Document Type: Article

References (76)

1. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013;339(6127):1567-1570.
2. Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058-1066.
3. Ezoe S. Secondary leukemia associated wit h the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health. 2012;9(7):2444-2453.
4. Krivtsov AV,Armstrong SA MLL translocations, histone modifications and leukaemia stem-cell development Nat Rev Cancer. 2007 7 11 823-833.
5. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009;23(8):1490-1499.
6. Hess JL. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med. 2004;10(10):500-507.
7. Ernst P, Fisher JK, Avery W, Wade S, Foy D, Korsmeyer SJ. Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev Cell. 2004;6(3):437-443.
8. Hemmati HD, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003;100(25):15178-15183.
9. Sureban SM, et al. Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology. 2008;134(5):1448-1458.
10. Oskarsson T, et al. Breast c ancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nature. 2011;17(7):867-874.
11. Barbouti A, et al. A novel gene, MSI2, encoding a putative RNA-binding protein is re currently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23). Cancer Res. 2003;63(6):1202-1206.
12. Saleki R, et al. A novel TTC40-MSI2 fusion in de novo acute myeloid leukemia with an unbalanced 10;17 translocation [published online ahead of print August 20, 2014]. Leuk Lymphoma. doi:10.3109/10428194.2014.947611.
13. Mu Q, et al. High expression of Musashi-2 indicates poor prognosis in adult B-cell acute lymphoblastic leukemia. Leuk Res. 2013; 37(8):922-927.
14. Ito T, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 2010;466(7307):765-768.
15. Kharas MG, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010;16(8):903-908.
16. Park S-M, et al. Musashi-2 controls cell fate, lineage bias, and TGF-? signaling in HSCs. J Exp Med. 2014;211(1):71-87.
17. Byers RJ, Currie T, Tholouli E, Rodig SJ, Kutok JL. MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia. Blood. 2011;118(10):2857-2867.
18. de André s-Aguayo L, et al. Musashi 2 is a regulator of the HSC compartment identified by a retroviral insertion screen and knockout mice. Blood. 2011;118(3):554-564.
19. Hope KJ, et al. An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity. Cell Stem Cell. 2010;7(1):101-113.
20. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer. 2003;3(3):179-192.
21. Kolle G, et al. Deep-transcriptome and ribonome sequencing redefines the molecular networks of pluripotency and the extracellular space in human embryonic stem cells. Genome Res. 2011;21(12):2014-2025.
22. Devlin EE, Dacosta L, Mohandas N, Elliott G, Bodine DM. A transgenic mouse model demonstrates a dominant negative effect of a point mutation in the RPS19 gene associated with Diamond-Bl ackfan anemia. Blood. 2010;116(15):2826-2835.
23. Draptchin skaia N, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999;21(2):169-175.
24. Narla A, Ebert BL. Translational medicine: ribosomopathies. Blood. 2011;118(16):4300-4301.
25. Hsieh AC,et al The translational landscape of mTOR signalling steers cancer initiation and metastasis Nature. 2012 485 7396 55-61.
26. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell. 2003;12(4):889-901.
27. Parsa AT, Holland EC. Cooperative translational control of gene expression by Ras and Akt in cancer. Trends Mol Med. 2004;10(12):607-613.
28. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer. 2010;10(4):254-266.
29. Krivtsov AV, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104):818-822.
30. Guenther MG, et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008;22(24):3403-3408.
31. Bernt KM, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20(1):66-78.
32. Zuber J, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011;25(15):1628-1640.
33. Somervaille TCP, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006;10(4):257-268.
34. Zhang H, et al. Musashi 2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway. Exp Cell Res. 2014;320(1):119-127.
35. Chan G, Gu S, Neel BG. Erk1 and Erk2 are required for maintenance of hematopoietic stem cells and adult hematopoiesis. Blood. 2013;121(18):3594-3598.
36. Li Q, et al. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature. 2013;504(7478):143-147.
37. Zuber J, et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009;23(7):877-889.
38. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
39. Jaatinen T, et al. Global gene expression profile of human cord blood-derived CD133+ cells. Stem Cells. 2006;24(3):631-641.
40. Brown AL, et al. Genetic regulators of myelopoiesis and leukemic signaling identified by gene profiling and linear modeling. J Leukoc Biol. 2006;80(2):433-447.
41. Patel JP, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.
42. Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differenti ation. Cancer Cell. 2010;18(6):553-567.
43. Wang Y, et al. The Wnt/?-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010; 327(5973):1650-1653.
44. Mullighan CG, et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia. 2007;21(9):2000-2009.
45. Hess JL, et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood. 2006;108(1):297-304.
46. Artinger EL, Ernst P. Cell context in the control of self-renewal and proliferation regulated by MLL1. Cell Cycle. 2013;12(18):2969-2972.
47. Jude CD, Climer L, Xu D, Art inger E, Fisher JK, Ernst P. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell. 2007;1(3):324-337.
48. Thiel AT, et al. MLL-AF9-indu ced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell. 2010;17(2):148-159.
49. Artinger EL, et al. An MLL-dependent network sustains hematopoiesis. Proc Natl Acad Sci U S A. 2013;110(29):12000-12005.
50. Jin S, Zhao H, Yi Y, Nakata Y, Kalota A, Gewirtz AM. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-Associated leukemog enesis. J Clin Invest. 2010;120(2):593-606.
51. King B, et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell. 2013;153(7):1552-1566.
52. Kuo HP, et al. Epigenetic roles of MLL oncoproteins are dependent on NF-?B. Cancer Cell. 2013;24(4):423-437.
53. Shi J, et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev. 2013;27(24):2648-2662.
54. Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-Associated antiapoptotic mutations. Blood. 2005; 106(7):2452-2461.
55. Holmfeldt L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3):242-252.
56. Grzanka J, et al. FoxP3, Helios, and SATB1: roles and relationships in regulatory T cells. Int Immunopharmacol. 2013;16(3):343-347.
57. Fujimoto R, Ozawa T, Itoyama T, Sadamori N, Kurosawa N, Isobe M. HELI OS-BCL11B fusion gene involvement in a t(2;14)(q34;q32) in an adult T-cell leukemia patient. Cancer Genet. 2012;205(7):356-364.
58. Krivtsov AV, et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia. 2013;27(4):852-860.
59. Thol F, et al. Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. Ann Hematol. 2013;92(3):315-323.
60. Kawahara H, Imai T, Imataka H, Tsujimoto M, Matsumoto K, Okano H. Neural RNA-binding protein Musashi1 inhibits translation initiation by competing with eIF4G for PA BP. J Cell Biol. 2008;181(4):639-653.
61. Rutledge CE, et al. Efficient translation of Dnmt1 requires cytoplasmic polyadenylation and Musashi binding elements. PLoS One. 2014;9(2):e88385.
62. Katz Y, et al. Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state [published online ahead of print November 7, 2014]. Elife. doi:10.7554/eLife.03915.
63. Daigle SR, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65.
64. Daigle SR, et al. Pot ent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013;122(6):1017-1025.
65. Schenk T, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18(4):605-611.
66. Harris WJ, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21(4):473-487.
67. Miller PG, et al. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin ?3 signaling. Cancer Cell. 2013;24(1):45-58.
68. Hahn CK,et al Proteomic and genetic approaches identify Syk as an AML target Cancer Cell. 2009 16 4, 281-294.
69. Jiang X, et al. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-Associated leukemia. Cancer Cell. 2012;22(4):524-535.
70. Kim J, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 2010; 143(2):313-324.
71. Sroczynska P, et al. shRNA screeni ng identifies JMJD1C as being required for leukemia maintenance. Blood. 2014;123(12):1870-1882.
72. Zuber J, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524-528.
73. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114-2120.
74. Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
75. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11(10):R106.
76. Fernandez HF, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.